SAN DIEGO, Calif. –By Lee Han-soo/Korea Biomedical Review correspondent -- The 66th American Society of Hematology (ASH) commenced its four-day annual meeting in San Diego, California, last Saturday, at the San Diego Convention Center.

This year's conference has attracted over 30,000 health professionals, clinicians, and researchers from around the globe, both in person and virtually.

The event features more than 275 exhibitors, including pharmaceutical companies, medical suppliers, and research-based organizations, showcasing the latest advancements in hematology.

A record-breaking number of abstracts were submitted, with over 7,950 accepted for presentation, highlighting cutting-edge research in the field.

Notably, the conference will address critical topics such as the evolving treatment landscape for chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML), advancements in CAR-T cell therapy, and management strategies for sickle cell disease.

 

Leading blood disorder specialists and pharmaceutical firms converged on California's coast for the 2023 ASH Annual Meeting. The four-day gathering, hosted at the San Diego Convention Center, serves as a premier forum for breakthroughs in blood-related diseases and treatments. From the weekend through midweek, researchers and clinicians share their latest findings in hematological medicine.
Leading blood disorder specialists and pharmaceutical firms converged on California's coast for the 2023 ASH Annual Meeting. The four-day gathering, hosted at the San Diego Convention Center, serves as a premier forum for breakthroughs in blood-related diseases and treatments. From the weekend through midweek, researchers and clinicians share their latest findings in hematological medicine.
At ASH 2024, Novartis is showcasing data from a variety of abstracts, emphasizing advancements in hematologic treatments. Highlights ｉｎｃｌｕｄｅ 96-week results from the phase 3 ASC4FIRST trial of Scemblix, demonstrating safety and tolerability in chronic myeloid leukemia, and interim phase II data for Ianalumab in immune thrombocytopenia. Updates on rapcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma and 48-week results for Fabhalta in paroxysmal nocturnal hemoglobinuria reveal improved patient outcomes. Additionally, phase III findings for Pelabresib in combination with ruxolitinib for myelofibrosis patients underline Novartis’s commitment to addressing unmet needs in hematology.
At ASH 2024, Novartis is showcasing data from a variety of abstracts, emphasizing advancements in hematologic treatments. Highlights ｉｎｃｌｕｄｅ 96-week results from the phase 3 ASC4FIRST trial of Scemblix, demonstrating safety and tolerability in chronic myeloid leukemia, and interim phase II data for Ianalumab in immune thrombocytopenia. Updates on rapcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma and 48-week results for Fabhalta in paroxysmal nocturnal hemoglobinuria reveal improved patient outcomes. Additionally, phase III findings for Pelabresib in combination with ruxolitinib for myelofibrosis patients underline Novartis’s commitment to addressing unmet needs in hematology.
AstraZeneca is showcasing 57 abstracts at ASH 2024, highlighting 13 approved and investigational therapies that reflect its dedication to advancing hematologic care. Key findings ｉｎｃｌｕｄｅ interim phase 3 AMPLIFY trial results for Calquence, demonstrating efficacy in combination with venetoclax for chronic lymphocytic leukemia, and promising phase 1 data for AZD0486, a CD19xCD3 bispecific T-cell engager, showing high response rates in lymphoma. Early results for AZD0120, a BCMAxCD19 dual-targeting CAR T-cell therapy, reveal deep responses in transplant-ineligible multiple myeloma patients, while new analyses for Voydeya confirm its safety and efficacy in addressing extravascular hemolysis in paroxysmal nocturnal hemoglobinuria. These findings highlight AstraZeneca’s transformative contributions to hematology.
AstraZeneca is showcasing 57 abstracts at ASH 2024, highlighting 13 approved and investigational therapies that reflect its dedication to advancing hematologic care. Key findings ｉｎｃｌｕｄｅ interim phase 3 AMPLIFY trial results for Calquence, demonstrating efficacy in combination with venetoclax for chronic lymphocytic leukemia, and promising phase 1 data for AZD0486, a CD19xCD3 bispecific T-cell engager, showing high response rates in lymphoma. Early results for AZD0120, a BCMAxCD19 dual-targeting CAR T-cell therapy, reveal deep responses in transplant-ineligible multiple myeloma patients, while new analyses for Voydeya confirm its safety and efficacy in addressing extravascular hemolysis in paroxysmal nocturnal hemoglobinuria. These findings highlight AstraZeneca’s transformative contributions to hematology.
Johnson & Johnson is presenting over 90 abstracts at ASH 2024, highlighting advancements in multiple myeloma, B- cell malignancies, and autoimmune disorders. Key studies ｉｎｃｌｕｄｅ the AQUILA trial on Darzalex Faspro for high-risk smoldering multiple myeloma, CARTITUDE-4 on Carvykti in lenalidomide-refractory multiple myeloma, and MajesTEC studies on Tecvayli in newly diagnosed cases. These findings emphasize J&J's commitment to improving hematologic care.[caption 5] Amgen is showcasing new data at ASH 2024, focusing on Blincyto for acute lymphoblastic leukemia, Kyprolis for multiple myeloma, and advancements in its biosimilar programs. These presentations highlight Amgen's commitment to improving hematologic care.
Johnson & Johnson is presenting over 90 abstracts at ASH 2024, highlighting advancements in multiple myeloma, B- cell malignancies, and autoimmune disorders. Key studies ｉｎｃｌｕｄｅ the AQUILA trial on Darzalex Faspro for high-risk smoldering multiple myeloma, CARTITUDE-4 on Carvykti in lenalidomide-refractory multiple myeloma, and MajesTEC studies on Tecvayli in newly diagnosed cases. These findings emphasize J&J's commitment to improving hematologic care.[caption 5] Amgen is showcasing new data at ASH 2024, focusing on Blincyto for acute lymphoblastic leukemia, Kyprolis for multiple myeloma, and advancements in its biosimilar programs. These presentations highlight Amgen's commitment to improving hematologic care.
Amgen is showcasing new data at ASH 2024, focusing on Blincyto for acute lymphoblastic leukemia, Kyprolis for multiple myeloma, and advancements in its biosimilar programs. These presentations highlight Amgen's commitment to improving hematologic care.
Amgen is showcasing new data at ASH 2024, focusing on Blincyto for acute lymphoblastic leukemia, Kyprolis for multiple myeloma, and advancements in its biosimilar programs. These presentations highlight Amgen's commitment to improving hematologic care.
Takeda is presenting key data at ASH 2024, including a five-year follow-up from the phase 2 OPTIC study on Iclusig for chronic-phase CML, and analyses from the PhALLCON trial on ICLUSIG in Philadelphia chromosome-positive acute lymphoblastic leukemia. Additional presentations ｉｎｃｌｕｄｅ findings on Adcetris for advanced-stage Hodgkin lymphoma, highlighting Takeda’s focus on advancing treatments for hematologic diseases.
Takeda is presenting key data at ASH 2024, including a five-year follow-up from the phase 2 OPTIC study on Iclusig for chronic-phase CML, and analyses from the PhALLCON trial on ICLUSIG in Philadelphia chromosome-positive acute lymphoblastic leukemia. Additional presentations ｉｎｃｌｕｄｅ findings on Adcetris for advanced-stage Hodgkin lymphoma, highlighting Takeda’s focus on advancing treatments for hematologic diseases.
AbbVie is showcasing data on ABBV-383, a BCMA-targeting bispecific T-cell engager for relapsed multiple myeloma, with promising response rates of up to 82 percent in combination with daratumumab and dexamethasone, highlighting its efforts to advance hematologic therapies.
AbbVie is showcasing data on ABBV-383, a BCMA-targeting bispecific T-cell engager for relapsed multiple myeloma, with promising response rates of up to 82 percent in combination with daratumumab and dexamethasone, highlighting its efforts to advance hematologic therapies.
GSK is presenting data on Blenrep for relapsed/refractory multiple myeloma, with the DREAMM-7 trial showing a 59 percent reduced risk of disease progression or death compared to a daratumumab regimen, emphasizing its advancements in multiple myeloma treatment.
GSK is presenting data on Blenrep for relapsed/refractory multiple myeloma, with the DREAMM-7 trial showing a 59 percent reduced risk of disease progression or death compared to a daratumumab regimen, emphasizing its advancements in multiple myeloma treatment.
Kite, a Gilead Company, is presenting 18 abstracts on CAR T-cell therapies, including Yescarta and Tecartus, showing strong survival outcomes and safety profiles.
Kite, a Gilead Company, is presenting 18 abstracts on CAR T-cell therapies, including Yescarta and Tecartus, showing strong survival outcomes and safety profiles.
Merck, known as MSD outside of the U.S. and Canada, is showcasing over 20 abstracts, including phase 2 data on zilovertamab vedotin in untreated DLBCL, nemtabrutinib in relapsed follicular lymphoma, and Keytruda in low-risk classical Hodgkin lymphoma, highlighting advancements in blood cancer treatments.
Merck, known as MSD outside of the U.S. and Canada, is showcasing over 20 abstracts, including phase 2 data on zilovertamab vedotin in untreated DLBCL, nemtabrutinib in relapsed follicular lymphoma, and Keytruda in low-risk classical Hodgkin lymphoma, highlighting advancements in blood cancer treatments.
Pfizer is presenting over 75 abstracts, including data on Adcetris for relapsed/refractory DLBCL, Elrexfio for multiple myeloma, and SEA-CD70 for high-risk myelodysplastic syndromes, highlighting advancements in hematology and oncology.
Pfizer is presenting over 75 abstracts, including data on Adcetris for relapsed/refractory DLBCL, Elrexfio for multiple myeloma, and SEA-CD70 for high-risk myelodysplastic syndromes, highlighting advancements in hematology and oncology.
Sanofi is presenting 49 abstracts, including data on rilzabrutinib for immune thrombocytopenia, Sarclisa in multiple myeloma, and pivotal findings on fitusiran and Altuviiio in hemophilia, highlighting advancements in hematology care.
Sanofi is presenting 49 abstracts, including data on rilzabrutinib for immune thrombocytopenia, Sarclisa in multiple myeloma, and pivotal findings on fitusiran and Altuviiio in hemophilia, highlighting advancements in hematology care.
BMS is presenting over 90 abstracts, including five-year survival data for Breyanzi in large B-cell lymphoma, Reblozyl data in myelodysplastic syndromes, and promising results for iberdomide in multiple myeloma, showcasing advancements in hematology.
BMS is presenting over 90 abstracts, including five-year survival data for Breyanzi in large B-cell lymphoma, Reblozyl data in myelodysplastic syndromes, and promising results for iberdomide in multiple myeloma, showcasing advancements in hematology.
BeiGene is presenting 21 abstracts, including five-year data from the SEQUOIA study on Brukinsa in CLL, promising Phase 1 results for BTK degrader BGB-16673, and strong findings for sonrotoclax combined with Brukinsa in treatment-naïve CLL, showcasing advancements in B-cell malignancies.
BeiGene is presenting 21 abstracts, including five-year data from the SEQUOIA study on Brukinsa in CLL, promising Phase 1 results for BTK degrader BGB-16673, and strong findings for sonrotoclax combined with Brukinsa in treatment-naïve CLL, showcasing advancements in B-cell malignancies.

 

Related articles

Copyright © KBR Unauthorized reproduction, redistribution prohibited